Drugs / RO5313534
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01196065 | Sep → Nov 2010 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00884507 | May 2009 → Nov 2010 | Alzheimer disease | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5313534 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00884507 ↗ |
| Known as | MEM3454 | “This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil” NCT00884507 ↗ |
| Route | Oral | “1mg po daily for 24 weeks” NCT00884507 ↗ |